The FDA provided positive feedback to Anebulo Pharmaceuticals (NASDAQ:ANEB) for its Phase 3 program of ANEB-001 in patients suffering from acute cannabinoid intoxication (ACI) and substance abuse.
Tag - ANEB
Copyright © 2024 BioTuesday Publishing Corporation - Privacy Policy